gefitinib has been researched along with apatinib in 6 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (apatinib) | Trials (apatinib) | Recent Studies (post-2010) (apatinib) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 575 | 109 | 544 |
| Protein | Taxonomy | gefitinib (IC50) | apatinib (IC50) |
|---|---|---|---|
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.001 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 4 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, B; Li, F; Liang, L; Wang, J; Zhu, T | 1 |
| Fang, W; Hong, S; Huang, Y; Luo, F; Ma, Y; Yang, Y; Zhang, L; Zhang, Y; Zhang, Z; Zhao, H | 1 |
| Chen, J; Li, X; Liu, H; Liu, M; Zhang, H | 1 |
| Dai, Y; Jin, M; Shi, D; Wang, C; Ying, L; Zhang, F; Zhou, Z | 1 |
| Cui, J; Du, X; Fan, Y; Fang, Y; Fu, X; Gu, K; Gu, W; Hou, Z; Hu, C; Jiang, O; Liu, J; Miao, L; Min, X; Wang, Q; Wu, G; Yao, W; Yu, G; Yu, Q; Yuan, X; Zhang, L; Zhang, Z; Zhao, H; Zheng, R; Zhou, X; Zhu, X | 1 |
| Chen, Q; Fang, W; Hou, Z; Huang, Y; Li, S; Liu, Q; Ma, Y; Wang, J; Xue, J; Yang, Y; Zhang, L; Zhang, Y; Zhao, H; Zhao, Y | 1 |
3 trial(s) available for gefitinib and apatinib
| Article | Year |
|---|---|
The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Double-Blind Method; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Multicenter Studies as Topic; Mutation; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic | 2019 |
Clinical study of apatinib combined with EGFR-TKI in the treatment of chronic progression after EGFR-TKI treatment in non-small cell lung cancer (ChiCTR1800019185).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Prospective Studies; Pyridines; Quinazolines; Research Design; Young Adult | 2020 |
Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706).
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pyridines; Quality of Life; Quinazolines; Vascular Endothelial Growth Factor A | 2021 |
3 other study(ies) available for gefitinib and apatinib
| Article | Year |
|---|---|
Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Pyridines; Quinazolines; Retrospective Studies; Signal Transduction; Time Factors; Treatment Outcome; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2017 |
An investigation into possible interactions among four vascular epidermal growth factor receptor-tyrosine kinase inhibitors with gefitinib.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Drug Interactions; ErbB Receptors; Gefitinib; Humans; Male; Microsomes, Liver; Molecular Docking Simulation; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley | 2021 |
Pharmacokinetics, safety, tolerability, and feasibility of apatinib in combination with gefitinib in stage IIIB-IV EGFR-mutated non-squamous NSCLC: a drug-drug interaction study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Feasibility Studies; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2023 |